We are live on ! Find out more
GFM

GF Fund Management Portfolio holdings

AUM $5.98B
1-Year Est. Return 80.99%
This Fund
S&P 500
This Quarter Est. Return
+10.72%
1 Year Est. Return
+80.99%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$5.85B
AUM Growth
+$338M
Cap. Flow
+$79.4M
Cap. Flow %
1.36%
Top 10 Hldgs %
45.51%
Holding
707
New
76
Increased
198
Reduced
354
Closed
64

Top Buys

Rank Stock Value
1
TER icon
Teradyne
TER
+$60.1M
2
TSLA icon
Tesla
TSLA
+$32.1M
3
TSEM icon
Tower Semiconductor
TSEM
+$29.6M
4
GOOG icon
Alphabet (Google) Class C
GOOG
+$29M
5
PDD icon
Pinduoduo
PDD
+$28.1M

Top Sells

Rank Stock Value
1
AVGO icon
Broadcom
AVGO
+$77.7M
2
BE icon
Bloom Energy
BE
+$53.1M
3
HOOD icon
Robinhood
HOOD
+$24.9M
4
SAP icon
SAP
SAP
+$24.1M
5
BIDU icon
Baidu
BIDU
+$21.5M

Sector Composition

Rank Sector Weight
1 Technology 51.21%
2 Communication Services 15.38%
3 Consumer Discretionary 13.01%
4 Healthcare 6.62%
5 Consumer Staples 4.41%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
TECX
601
Tectonic Therapeutic
TECX
$538M
$7.66K ﹤0.01%
367
-36
-9% -$669
RCKT icon
602
Rocket Pharmaceuticals
RCKT
$351M
$7.46K ﹤0.01%
2,125
-196
-8% -$671
ALT icon
603
Altimmune
ALT
$580M
$7.4K ﹤0.01%
2,049
+150
+8% +$654
BFS
604
Saul Centers
BFS
$850M
$7.06K ﹤0.01%
224
-1
-0.4% -$31
AURA icon
605
Aura Biosciences
AURA
$735M
$6.8K ﹤0.01%
1,247
-89
-7% -$529
BCYC
606
Bicycle Therapeutics
BCYC
$280M
$6.44K ﹤0.01%
909
-86
-9% -$634
ACRS icon
607
Aclaris Therapeutics
ACRS
$743M
$6.41K ﹤0.01%
+2,128
New +$5.38K
LRMR icon
608
Larimar Therapeutics
LRMR
$398M
$6.4K ﹤0.01%
1,680
-161
-9% -$626
AVXL icon
609
Anavex Life Sciences
AVXL
$250M
$6.25K ﹤0.01%
1,755
-93
-5% -$570
NGNE icon
610
Neurogene
NGNE
$670M
$6.22K ﹤0.01%
302
-14
-4% -$348
ACIU icon
611
AC Immune
ACIU
$241M
$6.19K ﹤0.01%
1,972
-188
-9% -$593
CADL icon
612
Candel Therapeutics
CADL
$723M
$6.09K ﹤0.01%
+1,078
New +$5.8K
LFCR icon
613
Lifecore Biomedical
LFCR
$164M
$6.02K ﹤0.01%
+736
New +$5.45K
FHTX icon
614
Foghorn Therapeutics
FHTX
$278M
$6K ﹤0.01%
1,111
-81
-7% -$367
MENS
615
Jyong Biotech
MENS
$166M
$5.9K ﹤0.01%
+1,493
New +$52.7K
PBYI icon
616
Puma Biotechnology
PBYI
$402M
$5.88K ﹤0.01%
+989
New +$5.25K
NMRA icon
617
Neumora Therapeutics
NMRA
$306M
$5.88K ﹤0.01%
3,282
-202
-6% -$442
ALLO icon
618
Allogene Therapeutics
ALLO
$680M
$5.86K ﹤0.01%
4,278
-496
-10% -$654
SLN
619
Silence Therapeutics
SLN
$549M
$5.61K ﹤0.01%
922
-56
-6% -$359
AARD
620
Aardvark Therapeutics
AARD
$140M
$5.6K ﹤0.01%
+427
New +$5.33K
AVIR icon
621
Atea Pharmaceuticals
AVIR
$379M
$5.48K ﹤0.01%
1,534
-220
-13% -$699
OABI icon
622
OmniAb
OABI
$288M
$5.23K ﹤0.01%
2,828
+241
+9% +$419
CTNM
623
Contineum Therapeutics
CTNM
$589M
$5.19K ﹤0.01%
+454
New +$5.18K
VYGR icon
624
Voyager Therapeutics
VYGR
$189M
$4.63K ﹤0.01%
1,178
-15
-1% -$66
OBIO icon
625
Orchestra BioMed
OBIO
$239M
$4.6K ﹤0.01%
+1,109
New +$4.47K
23 24
25
26 27

Similar funds

CM
CastleKnight Management New York $6B AUM 121.87% 1-Year Est. Return
BP
BC Partners New York $5.96B AUM 15.21% 1-Year Est. Return
AAM
Advisors Asset Management Monument, Colorado $6.01B AUM 24.74% 1-Year Est. Return
CAG
Crestwood Advisors Group Boston, Massachusetts $5.94B AUM 18.44% 1-Year Est. Return
RCG
Ruane, Cunniff & Goldfarb New York $6.03B AUM 12.06% 1-Year Est. Return
AL
Appaloosa LP Short Hills, New Jersey $5.93B AUM 44.55% 1-Year Est. Return
CGPCS
Capital Group Private Client Services Los Angeles, California $5.93B AUM 27.73% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

GF Fund Management's Q4 2025 Portfolio in Review

As of Q4 2025, GF Fund Management held 707 positions worth $5.85B, up 6.1% from $5.51B the previous quarter. Its ten largest holdings account for 46% of the portfolio.

GF Fund Management's Q4 2025 filing shows 76 new, 198 increased, 354 reduced and 64 closed positions. Its largest new stake was Teradyne: 350,137 shares worth $67.8M. The largest sale was Broadcom, an estimated $77.7M.

By sector, the portfolio is most concentrated in Technology at 51% of assets, up from 49% a quarter earlier, followed by Communication Services and Consumer Discretionary.

  • GF Fund Management's largest Q4 2025 buy was Teradyne: 350,137 shares worth $67.8M.
  • GF Fund Management added most to Tesla in Q4 2025, an estimated $32.1M increase.
  • GF Fund Management's biggest Q4 2025 reduction was Broadcom, cutting an estimated $77.7M.
  • GF Fund Management fully exited Baidu in Q4 2025, selling an estimated $21.5M.
  • GF Fund Management's ten largest holdings make up 46% of its $5.85B portfolio in Q4 2025.
  • GF Fund Management opened 76 new positions and closed 64 in Q4 2025.
  • GF Fund Management's portfolio value rose 6.1% quarter-over-quarter to $5.85B.

Based on GF Fund Management's 13F filing for Q4 2025, filed 27 Jan 2026.